Second Circuit Clarifies Removal Challenges in Upholding Eliquis Dismissal
The appellate panel resolved a district court split in the circuit over the reading of federal removal rules, agreeing with the district court that holding to the strict text was appropriate.
March 26, 2019 at 03:00 PM
5 minute read
In a 21-page order, the U.S. Court of Appeals for the Second Circuit on Tuesday upheld the dismissal of dozens of products liability lawsuits initiated across the country against Bristol‐Myers Squibb Co. and Pfizer Inc. over their blood-thinning medication Eliquis.
The order resolved a split among district courts in the circuit over the proper interpretation of federal forum defendant rules.
The issue arose out of the underlying multidistrict litigation that eventually made its way before U.S. District Judge Denise Cote of the Southern District of New York. Dozens of suits were brought, usually under state-law claims, claiming the drug companies did not properly warn consumers about the bleeding risks of Eliquis.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250